For Immediate Release
(Los Angeles, CA. November 1st, 2013) - DxTerity Diagnostics has been awarded a $280K SBIR contract by the National Cancer Institute (NCI) for the development of a molecular diagnostic test for predicting adverse response to radiation therapy.
|Dr. Percy Lee|
Over 1.6 million new cancer cases are diagnosed each year in the U.S, and over half of the patients are treated with some form of radiation therapy. While new technologies continue to improve the accuracy and overall safety of radiotherapy, approximately 5-10% of the patients will suffer moderate to severe side effects caused by a poor tolerance for ionizing radiation. The Radiation Toxicity test is designed to identify patients who might have higher susceptibility to radiation toxicity. This information will aid physicians in the optimization of cancer treatment protocols and improve patient safety.
DxTerity will be collaborating with Dr. Percy Lee, Chief of Thoracic and GI Radiation Oncology at the University of California Los Angeles (UCLA) Jonsson Comprehensive Cancer Center. Dr. Lee will serve as co-Principal Investigator and brings his clinical expertise in multiple radiotherapeutic modalities used for the treatment of cancer.
According to Bob Terbrueggen, Founder and CEO of DxTerity, “This new diagnostic test will build upon the expertise that DxTerity has developed in predicting a patient’s genomic response to ionizing radiation and provide a valuable tool for optimizing cancer treatment.”
About The UCLA Department of Radiation Oncology
The UCLA Department of Radiation Oncology's extraordinary patient care team leaders consist of innovative physicians, medical physicists and research scientists. This extraordinary team, coupled with the most state-of-the-art technology, creates the highest probability of superior treatment outcomes for cancer patients. Our outstanding researchers, leaders in their field, are able to take advantage of working within a world renown research university to create novel and innovative approaches to overcome difficult oncology problems.
Our faculty and staff are dedicated to delivering conscientious and compassionate care for our patients while offering attentive support to our patient's families. You will find that our "patient centered" approach is complimented by our mission to advance cancer treatment through research and its translation to patient care.
Contact Us » | Request an appointment » | Phone: (310) 825-9775
DxTerity is a molecular diagnostic company and clinical laboratory based in Rancho Dominguez, CA that is making genomic testing a routine part of medical care. DxTerity has developed the DxDirect genomic platform that enables simple, fast, and affordable measurement of genomic biomarkers from a single drop of blood.
DxTerity and DxDirect are registered trademarks of DxTerity Diagnostics, Inc.
DxTerity Diagnostics Inc.